Article Listing - Pharmaceutical
Pfizer’s Wyeth awarded UK contract to supply Prevenar 13; but drops European OTC ibuprofen/diphenhydramine development
20 January 2010
The UK Department of Health has confirmed that US drug behemoth Pfizer’s subsidiary, Wyeth, has been awarded the contract to supply Prevenar 13 (Pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) for the country’s childhood immunization program. This decision means that infants in the UK will receive the broadest available protection against pneumococcal disease, a leading cause of vaccine-preventable death in children younger than five years of age.
Idera gets $4.3 million clinical milestone under its cancer drug deal with Merck KGaA
20 January 2010
Massachusetts, USA-based Idera Pharmaceuticals says it has achieved a milestone of 3 million euros ($4.3 million) under its worldwide licensing and collaboration agreement with German drug major Merck KGaA, Darmstadt, Germany.
Larger proportion of hepatitis C non-responder patients in USA will get telaprevir therapy than boceprevir, study shows
20 January 2010
US gastroenterologists will treat a larger proportion of treatment non-responder hepatitis C patients with Vertex/Tibotec/Mitsubishi Tanabe’s telaprevir than Merck & Co’s boceprevir, according to news research from Decision Resources.
Polish laboratory diagnostics market expected to be worth $498 million 2012
20 January 2010
A range of factors will stimulate the growth of the in vitro (laboratory) diagnostics market in Poland in the next few years, according to the domestic market research and services company PMR.
Philippines seeks more voluntary drug price reductions
19 January 2010
For the second time in less than half a year, the Philippines government is calling on pharmaceutical companies, including global behemoth Pfizer and UK giant GlaxoSmithKline, to voluntarily halve their prices of some top-selling products, reports Bloomberg, Business Week and other news sources.
India’s Ranbaxy to enter vaccines market in deal with Biovel
19 January 2010
Indian drug major Ranbaxy Laboratories, which is 64% owned by Japan’s Daiichi Sankyo, has today signed an of agreements with Biovel Lifesciences based in Bangalore, India, to acquire the latter’s product rights and a manufacturing facility.
Boehringer Ingelheim and Priaxon collaborate on novel treatments for cancer
19 January 2010
German independent drug major Boehringer Ingelheim has entered into a worldwide collaboration with fellow Germany-based drug developer Priaxon to research and develop mdm2/p53 inhibitors for the treatment of cancer.
AstraZeneca and Dako in cancer test deal; Alcon buys eye-care product rights
19 January 2010
Two new product licensing agreements were announced yesterday: Anglo-Swedish drug major entered a deal with Dako Denmark A/S to collaborate on companion diagnostic tests for multiple AstraZeneca oncology projects, including biologics and small molecules, in various stages of discovery and development. Also, Alcon, the eye-care giant at the heart a full takeover accord by Swiss drug major Novartis (The Pharma Letter January 4), has acquired rights to two products from Sirion Therapeutics. Financial terms of neither transaction were revealed.
FDA warns US consumers about counterfeit weight-loss drug Alli
19 January 2010
The US Food and Drug Administration yesterday issued a warning to consumers about a counterfeit and potentially harmful version of the branded product Alli (which has as its active ingredient orlistat). The counterfeits in fact contained sibutramine, which should not be used by certain patients or without physician oversight and can interact in a harmful way with other medications, the FDA said.
Teva, Pfizer and EQT among final three bidders for Ratiopharm
19 January 2010
The German business daily Handelsblatt reports that acquisitive Israeli generics giant Teva Pharmaceutical Industries, global drugs behemoth Pfizer and the Swedish private equity fund EQT are the three finalists for privately-owned German generics drug company Ratiopharm GmbH, which was put up for sale after the suicide of its principal, Adolf Merckle, in January last year.
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
